The founders of Symphony Medical asked themselves how they could improve outcomes in atrial fibrillation patients with a procedure that would be faster than current ablative techniques and which wouldn't destroy heart tissue. The solution lies in a biopolymer that can achieve a biological effect on the heart, and it came, in a roundabout way, from cell therapy work begun in heart failure.
6520 Edenvale Boulevard Suite 230
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
